[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Nemenqani D, Yaqoob N, Hafiz M: Fine needle aspiration cytology of granulomatous mastitis with special emphasis on microbiologic correlation. Acta Cytol; 2009 Nov-Dec;53(6):667-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of granulomatous mastitis with special emphasis on microbiologic correlation.
  • OBJECTIVE: To describe the cytomorphology of granulomatous mastitis (GM) and to evaluate the causative agents involved, proven on the basis of microbiologic culture results and polymerase chain reaction (PCR) studies.
  • STUDY DESIGN: We retrospectively reviewed the inflammatory breast aspirates reported at King Abdul Aziz Specialist Hospital and Al Hada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia, from January 2000 until March 2008.
  • Cases of inflammatory carcinoma or duct ectasia were excluded.
  • RESULTS: A total of 49 cases of inflammatory breast aspirates were identified, of which 15 cases were GM.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Breast / microbiology. Breast / pathology. Mastitis / microbiology. Mastitis / pathology

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014556.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Kieffer P, Dukic R, Hueber M, Kieffer C, Bouhala M, Riegel P, Wilhelm JM: [A young woman with granulomatous mastitis: a corynebacteria may be involved in the pathogenesis of these disease]. Rev Med Interne; 2006 Jul;27(7):550-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A young woman with granulomatous mastitis: a corynebacteria may be involved in the pathogenesis of these disease].
  • [Transliterated title] Mastite granulomateuse récidivante chez une jeune femme: rôle potentiel de "corynebacterium kroppenstedtii".
  • INTRODUCTION: The granulomatous mastitis is an inflammatory pseudotumor of the breast of which evolution benign but likely to generate important morphological after-effects among young women.
  • This anatomoclinic entity of dubious etiology until these last years poses a problem of differential diagnosis with other etiologies of granulomatosis and especially with inflammatory carcinoma of the breast.
  • INTERPRETATION: A 26 years old young woman developed an inflammatory tumor of the left breast of which the catch of load by surgery and an antibiotherapy had shown trailing local continuations and of the esthetic after-effects.
  • One year later, a very inflammatory repetition on the level of the right breast was dealt with in a different way: by steroids and immunomodulating drugs associated with iterative punctures with the purulent collections, the objective being to be less dilapidating that left side.
  • CONCLUSION: This observation illustrates the therapeutic and diagnostic difficulties of an exceptional affection.

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750284.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 804826J2HU / Amoxicillin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J: High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer; 2001 Jun 15;84(12):1591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
  • Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with >or= 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (n = 53)] or with stage IV responsive breast cancer (n = 10) received paclitaxel 150-775 mg/m(2)infused over 24 hours, doxorubicin 165 mg/m(2)as a continuous infusion over 96 hours, and cyclophosphamide 100 mg kg(-1).
  • Kaplan-Meier estimates of 30-month event-free and overall survival for patients with primary breast carcinoma are 65% (95% CI; 51-83%) and 77% (95% CI; 64-93%).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):225-33 [10655439.001]
  • [Cites] Hematol Cell Ther. 1999 Apr;41(2):71-4 [10344555.001]
  • [Cites] Acta Oncol. 2000;39(1):47-52 [10752653.001]
  • [Cites] Ther Drug Monit. 1985;7(4):455-60 [4082243.001]
  • [Cites] Br J Cancer. 1989 Jul;60(1):121-5 [2478178.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1824-30 [2511276.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(2):159-64 [1982732.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1261-7 [1675263.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1132-43 [8501500.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1943-51 [7691998.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):532-8 [7907130.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1253-9 [8080512.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1678-85 [7512436.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1621-9 [7913721.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 8):19-23 [7939757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):180-90 [7799018.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1463-72 [8622060.001]
  • [Cites] J Infus Chemother. 1996 Spring;6(2):69-73 [8809652.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1521-8 [9057632.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1870-9 [9164197.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1906-15 [9164201.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2882-93 [9256132.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1689-95 [9676843.001]
  • [Cites] Lancet. 1998 Aug 15;352(9127):515-21 [9716055.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):847-54 [9816240.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1008-14 [9849448.001]
  • [Cites] N Engl J Med. 2000 Apr 13;342(15):1069-76 [10760307.001]
  • (PMID = 11401310.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33572; United States / NCI NIH HHS / CA / CA62505
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2363687
  •  go-up   go-down


Advertisement
4. Tanigawa T, Miyamoto Y, Abe M, Hasuo T, Doiguchi M, Sakamoto F: [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
  • We experienced a case of inflammatory carcinoma, which has been well controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab.
  • A 54-year-old woman was diagnosed as inflammatory carcinoma with T4d, N3c, M0 in Stage III c.
  • The lesion was diagnosed as invasive ductal carcinoma, scirrhous, ER(-), PgR(-), HER2(3+) by core needle biopsy, The skin lesion was diagnosed as dermal lymphatic carcinomatosis by skin biopsy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma / drug therapy. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Inflammation. Middle Aged. Oxonic Acid / administration & dosage. Skin Neoplasms / drug therapy. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755823.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 5VT6420TIG / Oxonic Acid; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


5. Maffini F, Baldini F, Bassi F, Luini A, Viale G: Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis. J Cutan Pathol; 2009 Jun;36(6):689-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis.
  • Idiopathic granulomatous mastitis clinically and histologically mimics an inflammatory carcinoma.
  • A correct approach including ultrasound, clinical and histological analysis can safely identify a patient with this pathology, orienting to adequate therapy with anti-inflammatory and antibiotic drugs and leaving the surgical approach only for case unresponsive to medical therapy.
  • [MeSH-major] Granuloma, Giant Cell / diagnosis. Mastitis / diagnosis
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Breast Neoplasms / pathology. Burkholderia Infections / drug therapy. Diagnosis, Differential. Female. Humans. Ulcer / drug therapy. Ulcer / microbiology

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222698.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents
  •  go-up   go-down


6. Vingerhoedt NM, Janssen S, Mravunac M, Wauters CA, Strobbe LJ: [Granulomatous lobular mastitis: a benign abnormality that mimics malignancy]. Ned Tijdschr Geneeskd; 2008 May 3;152(18):1052-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulomatous lobular mastitis: a benign abnormality that mimics malignancy].
  • [Transliterated title] Granulomateuze lobulaire mastitis: een benigne afwijking die imponeert als maligniteit.
  • A palpable abnormality of the breast was found in three women, one aged 57 and two aged 41.
  • The first two patients predominantly showed the characteristics of a purulent inflammation, and on mammogram the third patient appeared to have mastitis carcinomatosa.
  • Once again, medicinal treatment was given.
  • Granulomatous lobular mastitis is a rare and benign tumour of the breast that clinically mimics carcinoma.
  • [MeSH-major] Granuloma / diagnosis. Granuloma / drug therapy. Mastitis / diagnosis. Mastitis / drug therapy
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Azathioprine / therapeutic use. Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Middle Aged. Prednisone / therapeutic use. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547028.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Eaden J: Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther; 2004 Oct;20 Suppl 4:24-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: colorectal carcinoma and inflammatory bowel disease.
  • As surveillance is not 100% effective, alternative ways of reducing the cancer risk with chemopreventive agents, such as aminosalicylates, are being considered.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352890.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 58
  •  go-up   go-down


8. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther; 2003 Sep;18 Suppl 2:10-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
  • It is assumed that mesalazine may have similar genetic and molecular targets as nonsteroidal anti-inflammatory drugs (NSAIDs), which is further supported by its close similarity with aspirin, differing only in its structure by the presence of an amino group at position 5 of the benzene ring.
  • The putative chemopreventive actions include the inhibition of inflammatory cascades and/or reactions involved in cell growth and proliferation, such as cyclo-oxygenase (COX-1 and COX-2), which regulate cell proliferation through the formation of prostaglandins; lipoxygenase; nuclear factor kappaB (NFkappaB), responsible for the subsequent expression of pro-inflammatory molecules; MAP kinases and Bcl-2, as well as the activation of apoptotic processes, such as the stimulation of intestinal sphingomyelinase.
  • The peroxisome-proliferator-activated receptor delta (PPARdelta), which also regulates gene transcription, is thought to play a role in both inflammatory and non-inflammatory driven carcinogenesis.
  • It is hypothesized that 5-ASAs may prevent the enhancing effect of prostaglandins on PPARdelta binding to DNA by its COX inhibitory properties, decreasing proliferation of colorectal mucosal cells in non-inflammatory bowel disease patients with sporadic polyps of the large bowel.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Colorectal Neoplasms / prevention & control. Inflammatory Bowel Diseases / drug therapy. Mesalamine / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cyclooxygenase 1. Cyclooxygenase 2. DNA Damage. Humans. Isoenzymes / antagonists & inhibitors. Membrane Proteins. Prostaglandin-Endoperoxide Synthases. Reactive Oxygen Species / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MESALAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950415.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Reactive Oxygen Species; 4Q81I59GXC / Mesalamine; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 30
  •  go-up   go-down


9. Stammberger U, Steinacher C, Hillinger S, Schmid RA, Kinsbergen T, Weder W: Early and long-term complaints following video-assisted thoracoscopic surgery: evaluation in 173 patients. Eur J Cardiothorac Surg; 2000 Jul;18(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Two hundred and thirteen patients (of whom 79 females) with a mean age of 48 (range 15-88) years were operated on for a total of 225 procedures.
  • Various indications included therapeutic or diagnostic procedures in bullous disease, mediastinal tumors, carcinoma, inflammatory lung disease, hyperhidrosis mani and bronchiectasis.
  • One patient died on the ninth postoperative day after lobectomy for bronchial carcinoma due to cardiac failure, five patients needed a short period of reintubation due to acute respiratory failure.
  • Twelve percent needed pain medication regularly, and 3% occasionally.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2000 Dec;18(6):737-8 [11221734.001]
  • (PMID = 10869933.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down






Advertisement